2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants
1995
R-(+)-HA-966, an antagonist for the glycine/NMDA receptor, prevents locomotor sensitization to repeated cocaine exposures
Morrow B, Taylor J, Roth R. R-(+)-HA-966, an antagonist for the glycine/NMDA receptor, prevents locomotor sensitization to repeated cocaine exposures. Brain Research 1995, 673: 165-169. PMID: 7757472, DOI: 10.1016/0006-8993(94)01456-r.Peer-Reviewed Original ResearchConceptsGlycine/NMDA receptorHA-966Locomotor sensitizationLocomotor activationNMDA receptorsCocaine administrationSubsequent challenge doseLocomotor stimulant propertiesNMDA receptor complexAcute stimulant effectsChallenge doseReverse toleranceRepeated administrationAcute doseCocaine exposureStimulant effectsGlycine receptorsStimulant propertiesCocaineSensitizationAdministrationReceptorsReceptor complexAntagonistDose